DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/c73cdf/the_111th_u_s_con) has
announced the addition of Decision Resources, Inc.'s new report "The 111th U.S.
Congress Tackles Healthcare Reform and the Pharmaceutical Industry" to their
offering.
In this report, we feature a commentary by Alex M. Brill, CEO of Matrix Global
Advisors and a research fellow at the American Enterprise Institute, who
testified before the U.S. House Judiciary Committee's Subcommittee on Courts and
Competition on July 14, 2009, regarding data exclusivity for biosimilars. We
also provide insights from an interviewed health policy lobbyist who is active
in government affairs in Washington, D.C. He spoke on background concerning
recent negotiations on healthcare reform, authorized generics, and reverse
payment deals. Kevin E. Noonan, J.D., Ph.D., a partner at McDonnell Boehnen
Hulbert & Berghoff, gives his insights on patent reform and healthcare reform.
Key Topics Covered:
* Executive Summary
* Aggressive First Steps by the 111th Congress
* American Recovery and Reinvestment Act of 2009
* Importation of Drugs
* Authorized Generics and Pay-for-Delay Deals
* Biosimilars: Follow-On Biologics
* Patent Reform Act of 2009
* All Eyes Turn to Healthcare Reform
* Outlook
* Expert Commentaries
* Tables
* Figures
For more information visit
http://www.researchandmarkets.com/research/c73cdf/the_111th_u_s_con
Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Copyright Business Wire 2009
